SRXN1 and hepatocellular carcinoma: The 1‐year, 3‐year, and 5‐year AUC values showed SRXN1 had a good biomarker performance for HCC patients, especially in patients with poorly differentiated, advanced state or hepatitis B in the training cohort, and the results of the validated group confirmed the conclusion (Figure S2).